Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Biosimilar Norms: Patient Safety Debate Boils Over

Executive Summary

A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.

You may also be interested in...



Here’s What Competition Looks Like In India’s Humira Biosimilars Market

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

Here’s What Competition Looks Like In India’s Humira Biosimilars Market

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

Biocon: Japan Biosimilar Glargine Nod To Open Other Doors

India's largest biopharmaceutical company, Biocon, has reported quarterly net profit rocketed nearly 80% thanks to exceptional income, and says Japan's regulatory nod for its insulin glargine should help “fast-track” approvals of the biosimilar in both emerging markets and advanced economies.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel